Table II.
Three-year clinical outcomes according to prognostic factors.
| Factors | Overall survival (%) | P | Disease-free survival (%) | P | Disease-specific survival (%) | P | Local control (%) | P | Intra-hepatic control (%) | P | Distant metastasis-free rate (%) | P |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | ||||||||||||
| <60/≥60 | 78.1/80.9 | 0.13 | 62.4/40.5 | 0.67 | 82.0/80.9 | 0.42 | 91.7/86.6 | 0.36 | 72.7/46.4 | 0.33 | 97.6/97.8 | 0.93 |
| Gender | ||||||||||||
| M/F | 75.6/90.0 | 0.13 | 51.4/50.6 | 0.44 | 78.1/90.0 | 0.25 | 84.9/100.0 | 0.05 | 62.7/50.6 | 0.63 | 100.0/96.8 | 0.38 |
| pT | ||||||||||||
| pT1/pT2 | 90.6/71.1 | 0.08 | 61.1/43.0 | 0.09 | 93.0/72.5 | 0.02 | 92.1/86.3 | 0.38 | 69.0/50.5 | 0.05 | 100.0/95.8 | 0.20 |
| VI | ||||||||||||
| No/yes | 92.8/62.1 | <0.003a | 60.9/37.9 | <0.005a | 94.7/63.7 | <0.001a | 91.5/85.6 | 0.40 | 66.8/47.8 | 0.008a | 100.0/94.5 | 0.09 |
| Tumor size (mm) | ||||||||||||
| <50/≥50 | 81.8/72.1 | 0.24 | 52.3/46.0 | 0.34 | 84.3/72.1 | 0.08 | 88.9/88.9 | 0.97 | 59.2/57.3 | 0.43 | 98.5/95.0 | 0.34 |
| Surgical margin | ||||||||||||
| (+)/(-) | 75.0/79.3 | 0.95 | 50.0/50.8 | 0.84 | 75.0/81.3 | 0.75 | 100.0/88.5 | 0.53 | 66.7/58.2 | 0.59 | 100.0/97.6 | 0.77 |
| ≤1/>1 mm | 70.7/80.5 | 0.51 | 46.3/49.6 | 0.83 | 76.2/81.6 | 0.64 | 100.0/87.1 | 0.20 | 54.8/57.8 | 0.79 | 100.0/97.3 | 0.55 |
| ≤2/>2 mm | 81.0/78.2 | 0.76 | 45.7/50.8 | 0.93 | 84.8/79.5 | 0.68 | 100.0/85.5 | 0.08 | 50.5/60.2 | 0.66 | 100.0/96.9 | 0.42 |
| Stage | ||||||||||||
| I/II | 90.6/71.1 | 0.08 | 61.1/43.0 | 0.09 | 93.0/72.5 | 0.02a | 92.1/86.4 | 0.49 | 69.0/50.5 | 0.05a | 100.0/95.8 | 0.20 |
| BCLC stage | ||||||||||||
| 0 | 83.8 | 0.49 | 58.0 | 0.64 | 83.8 | 0.56 | 100.0 | 0.15 | 58.0 | 0.75 | 100.0 | 0.60 |
| A | 85.5 | 43.6 | 87.6 | 83.1 | 51.1 | 97.7 | ||||||
| B | 70.0 | 50.6 | 73.2 | 90.0 | 64.4 | 95.5 |
a
P<0.05. M, male; F, female; pT, pathological T stage; VI, vascular invasion; BCLC, Barcelona-Clinic Liver Cancer.